TABLE 1.
Characterization and relative distribution of the major cardiolipin species observed in commercial bovine heart cardiolipin products
| HPLC | MS | MS/MS | MS/MS | MS/MS | % of Total Determined Peak Area | |||
|---|---|---|---|---|---|---|---|---|
| Major Cardiolipin Species Observed | Retention Time (min) | Molecular Weight (Da) | Diacylglycerol-phosphate Fragment (m/z) | Monoacylglycerol- phosphate Fragment (m/z) | Fatty Acid Fragment (m/z) | MS XIC Range (m/z) | Avanti | Sigma |
| (C18:2)3(C18:3)1 | 28.0 | 1446 | 693, 695 | 413, 415 | 277, 279 | 1445-1447 | 1.9% | 5.6% |
| (C18:2)4 | 29.5 | 1448 | 695 | 415 | 279 | 1447-1449 | 72.6% | 69.7% |
| (C18:2)3(C18:1)1 | 31.3 | 1450 | 695, 697 | 415, 417 | 279, 281 | 1449-1451 | 17.9% | 19.2% |
| (C18:2)2(C18:1)2 | 33.0 | 1452 | 695, 697 | 415, 417 | 279, 281 | 1451-1453 | 4.1% | 4.6% |
| (C18:2)3(C18:0)1 | 34.0 | 1452 | 695, 699 | 415, 419 | 279, 283 | 1451-1453 | 3.5% | 0.5% |